AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8214547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 30 mg
Number of subjects: 100
Study 8214547 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine 75 mg
Number of subjects: 100
Study 8214547 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study 2443151 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy combined with bleomycin
Number of subjects: 110
Study 2443151 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy combined with a retinoid
Number of subjects: 110
Study 2443151 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery after irradiation
Number of subjects: 110
Study 2443151 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative therapy
Number of subjects: 110
Study 28712024 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee hyperextension during functional activities in ACL‐R knees.
Number of subjects: 42
Study 28712024 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum knee extension angle during running in ACL‐R knees.
Number of subjects: 42
Study 28712024 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-to-side difference (SSD) of internal tibial rotation during walking and running in ACL‐R knees.
Number of subjects: 42
Study 26315564 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteotome sinus floor elevation (OSFE) without grafting material
Number of subjects: 45
Study 26315564 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteotome sinus floor elevation (OSFE) with deproteinized bovine bone (DBB)
Number of subjects: 45
Study 26315564 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteotome sinus floor elevation (OSFE) with β‐tricalcium phosphate (β‐TCP)
Number of subjects: 45
Study 26315564 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteotome sinus floor elevation (OSFE) with β‐TCP and DBB combination
Number of subjects: 45
Study 25012498 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system inhibition (RASI) with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
Number of subjects: 1873
Study 22321388 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy
Number of subjects: 125
Study 22321388 — intervention group
Group type: COMPARATOR
Intervention: Mesh group
Number of subjects: 125
Study 22321388 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (subgroup analysis of women with a partner)
Number of subjects: 125
Study 22321388 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sexual functioning
Number of subjects: 125
Study 19776651 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided treatment
Number of subjects: 121
Study 19776651 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment based on conventional laboratory parameters
Number of subjects: 121
Study 18714171 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus gefitinib (pG)
Number of subjects: 82
Study 18714171 — intervention group
Group type: COMPARATOR
Intervention: Prednisone plus placebo (ppl)
Number of subjects: 82
Study 17194239 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% 1RM
Number of subjects: 16
Study 17194239 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% 1RM
Number of subjects: 16
Study 17194239 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% 1RM
Number of subjects: 16
Study 17194239 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench press at 90% 1RM
Number of subjects: 16
Study 17194239 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 16
Study 14578079 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly demanding secondary task
Number of subjects: 0
Study 14578079 — intervention group
Group type: COMPARATOR
Intervention: Less demanding secondary task
Number of subjects: 0
Study 10787068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 10 mg IM
Number of subjects: 60
Study 10787068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 20 mg IM
Number of subjects: 60
Study 10787068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 40 mg IM
Number of subjects: 60
Study 10787068 — intervention group
Group type: COMPARATOR
Intervention: Control (Chlorpheniramine maleate 20 mg IM)
Number of subjects: 60
Study 8955971 — intervention group
Group type: EXPERIMENTAL
Intervention: Genius
Number of subjects: 50
Study 8955971 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermopit
Number of subjects: 50
Study 8955971 — intervention group
Group type: EXPERIMENTAL
Intervention: Quickthermo
Number of subjects: 50
Study 8955971 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoscan
Number of subjects: 50
Study 8955971 — intervention group
Group type: COMPARATOR
Intervention: Mon‐a‐Therm thermocouples
Number of subjects: 50
Study 1471304 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 10
Study 1471304 — intervention group
Group type: COMPARATOR
Intervention: Control (historic control group)
Number of subjects: 10
Study 6148960 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol 0.1 mg/kg
Number of subjects: 8
Study 6148960 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 8
Study 6148960 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol
Number of subjects: 8
Study 30374040 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Office Blood Pressure (AOBP) using Omron HEM-907
Number of subjects: 108
Study 30374040 — intervention group
Group type: COMPARATOR
Intervention: Observed Office Blood Pressure (OOBP)
Number of subjects: 108
Study 30374040 — intervention group
Group type: COMPARATOR
Intervention: Awake Ambulatory Blood Pressure (AABP)
Number of subjects: 108
Study 30656171 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg per night and nocturnal splint
Number of subjects: 0
Study 30656171 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve and tendon gliding exercises and nocturnal splint
Number of subjects: 0
Study 30656171 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg per night, exercises, and nocturnal splint
Number of subjects: 0
Study 30656171 — intervention group
Group type: COMPARATOR
Intervention: Nocturnal splint (control group)
Number of subjects: 0
Study 26973734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear stress test (NucST)
Number of subjects: 240
Study 26973734 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nuclear stress test (Non-NucST)
Number of subjects: 240
Study 26973734 — intervention group
Group type: COMPARATOR
Intervention: Algorithm introduction
Number of subjects: 240
Study 25305703 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1800 mg/day initiated within 24 hours after PCI
Number of subjects: 115
Study 25305703 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPA treatment)
Number of subjects: 115
Study 23057726 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco-sponsored smoking cessation ads
Number of subjects: 270
Study 23057726 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health ads with tobacco company identification
Number of subjects: 270
Study 23057726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguous ad content
Number of subjects: 270
Study 23057726 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct ad content about health consequences of smoking
Number of subjects: 270
Study 20579863 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg Pycnogenol a day
Number of subjects: 98
Study 20579863 — intervention group
Group type: COMPARATOR
Intervention: Compression stockings only
Number of subjects: 98
Study 20579863 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Pycnogenol and elastic stockings
Number of subjects: 98
Study 18042893 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve blockade
Number of subjects: 62
Study 18042893 — intervention group
Group type: COMPARATOR
Intervention: IV analgesia with metamizol
Number of subjects: 62
Study 16534182 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (1 mg/day, n = 15)
Number of subjects: 30
Study 16534182 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 30
Study 12855831 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger subjects (mean age 28+/‐8 years)
Number of subjects: 50
Study 12855831 — intervention group
Group type: COMPARATOR
Intervention: Older subjects (mean age 69+/‐10 years)
Number of subjects: 50
Study 10559077 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 23
Study 10559077 — intervention group
Group type: EXPERIMENTAL
Intervention: Borg scale
Number of subjects: 23
Study 10559077 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg)
Number of subjects: 23
Study 10559077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 11361492 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site social work activities (postintervention)
Number of subjects: 594
Study 11361492 — intervention group
Group type: COMPARATOR
Intervention: Preintervention group
Number of subjects: 594
Study 11361492 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial postintervention group
Number of subjects: 594
Study 11361492 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term postintervention group
Number of subjects: 594
Study 1854026 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 5 micrograms/mL epinephrine
Number of subjects: 30
Study 1854026 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% 2-chloroprocaine
Number of subjects: 30
Study 1854026 — intervention group
Group type: COMPARATOR
Intervention: lidocaine
Number of subjects: 30
Study 6337670 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal dilator (no. 2) twice daily for 3 weeks
Number of subjects: 66
Study 6337670 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetic jelly without dilator for 3 weeks
Number of subjects: 66
Study 31261584 — intervention group
Group type: EXPERIMENTAL
Intervention: High CRP levels
Number of subjects: 192
Study 31261584 — intervention group
Group type: COMPARATOR
Intervention: Low CRP levels
Number of subjects: 192
Study 28137918 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecoaching intervention group (IG)
Number of subjects: 343
Study 28137918 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 343
Study 26852743 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management (ongoing therapy)
Number of subjects: 75
Study 26852743 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management with treatment crossover to endoscopic sinus surgery (ESS)
Number of subjects: 75
Study 25086763 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive behavior therapy (CBT)
Number of subjects: 54
Study 25086763 — intervention group
Group type: COMPARATOR
Intervention: Group cognitive behavior therapy (CBT)
Number of subjects: 54
Study 22001151 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciclosporin A (CsA) 2%
Number of subjects: 366
Study 22001151 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.1%
Number of subjects: 366
Study 19178574 — intervention group
Group type: EXPERIMENTAL
Intervention: AGTR1 1166A > C and AGT Met235Thr polymorphisms
Number of subjects: 25000
Study 17952523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical hand‐sewn anastomosis (CHS)
Number of subjects: 32
Study 17952523 — intervention group
Group type: COMPARATOR
Intervention: Intrathoracic stapled anastomosis (ITS)
Number of subjects: 32
Study 15642666 — intervention group
Group type: COMPARATOR
Intervention: sTfR in normal subjects
Number of subjects: 87
Study 15642666 — intervention group
Group type: EXPERIMENTAL
Intervention: sTfR in HH patients
Number of subjects: 87
Study 11728763 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl alcohol with epinephrine, 1:100,000 (BA)
Number of subjects: 52
Study 11728763 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine with epinephrine, 1:100,000 (LID)
Number of subjects: 52
Study 9387965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing after exposure to mouldy hay in patients with farmer's lung
Number of subjects: 36
Study 9387965 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary exercise testing in asymptomatic farmers
Number of subjects: 36
Study 9387965 — intervention group
Group type: COMPARATOR
Intervention: Comparison of patients with farmer's lung to asymptomatic farmers
Number of subjects: 36
Study 7940137 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol
Number of subjects: 44
Study 7940137 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol
Number of subjects: 44
Study 3764628 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ciprofloxacin
Number of subjects: 50
Study 3764628 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ciprofloxacin
Number of subjects: 50
Study 29504810 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.016-inch TiNbTaZr archwires
Number of subjects: 28
Study 29504810 — intervention group
Group type: COMPARATOR
Intervention: 0.016-inch NiTi archwires
Number of subjects: 28
Study 27722222 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implants
Number of subjects: 210
Study 27722222 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-delayed implants (6 weeks)
Number of subjects: 210
Study 27722222 — intervention group
Group type: COMPARATOR
Intervention: Delayed implants (4 months)
Number of subjects: 210
Study 24977750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved red blood cells (CPRBC)
Number of subjects: 57
Study 24977750 — intervention group
Group type: COMPARATOR
Intervention: Liquid preserved packed red blood cells (LPRBC)
Number of subjects: 57
Study 23484300 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education plus traditional patient education (TPE)
Number of subjects: 133
Study 23484300 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet education plus traditional patient education (TPE)
Number of subjects: 133
Study 23484300 — intervention group
Group type: COMPARATOR
Intervention: Traditional patient education (TPE) alone
Number of subjects: 133
Study 21426445 — intervention group
Group type: EXPERIMENTAL
Intervention: N8
Number of subjects: 0
Study 21426445 — intervention group
Group type: COMPARATOR
Intervention: Advate(®)
Number of subjects: 0
Study 21426445 — intervention group
Group type: EXPERIMENTAL
Intervention: N8 and Advate(®)
Number of subjects: 0
Study 18503141 — intervention group
Group type: COMPARATOR
Intervention: 20 mg tadalafil
Number of subjects: 8
Study 18503141 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nitrendipine
Number of subjects: 8
Study 18503141 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil + 5 mg nitrendipine
Number of subjects: 8
Study 18503141 — intervention group
Group type: COMPARATOR
Intervention: All protocols
Number of subjects: 8
Study 16580059 — intervention group
Group type: EXPERIMENTAL
Intervention: Skinsafe intervention
Number of subjects: 589
Study 12702127 — intervention group
Group type: EXPERIMENTAL
Intervention: Trizivir (abacavir-lamivudine-zidovudine combination tablet) administered twice daily
Number of subjects: 209
Study 12702127 — intervention group
Group type: COMPARATOR
Intervention: Continued treatment (two nucleoside reverse transcriptase inhibitors plus a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor or three nucleoside reverse transcriptase inhibitors)
Number of subjects: 209
Study 12702127 — intervention group
Group type: EXPERIMENTAL
Intervention: Trizivir (abacavir-lamivudine-zidovudine combination tablet)
Number of subjects: 209
Study 10752915 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide administered via AeroChamber, 750 microg (3 puffs), twice daily
Number of subjects: 176
Study 10752915 — intervention group
Group type: COMPARATOR
Intervention: Budesonide administered via Turbuhaler, 600 microg (3 puffs), twice daily
Number of subjects: 176
Study 9373479 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levobunolol HCl 0.5% (LEV)
Number of subjects: 15
Study 9373479 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (TEAR)
Number of subjects: 15
Study 9373479 — intervention group
Group type: COMPARATOR
Intervention: Topical levobunolol HCl 0.5% (LEV) vs Artificial tears (TEAR)
Number of subjects: 15
Study 1530166 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (2.5 micrograms/kg)
Number of subjects: 60
Study 1530166 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms/kg)
Number of subjects: 60
Study 1530166 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 60
Study 6754844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (screening and examination, barium meal examination for those with possible or probable peptic ulcer)
Number of subjects: 199
Study 6754844 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 199
Study 6754844 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 199
Study 31825472 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP) with active tDCS
Number of subjects: 68
Study 31825472 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-based relapse prevention (MBRP) with sham tDCS
Number of subjects: 68
Study 31825472 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 68
Study 31825472 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 68
Study 30336170 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Number of subjects: 20
Study 30336170 — intervention group
Group type: COMPARATOR
Intervention: Oxygen face mask
Number of subjects: 20
Study 27943153 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg BID days 1-28 plus Bevacizumab 2.5 mg/kg every other week (MTD)
Number of subjects: 24
Study 27943153 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg BID (phase I)
Number of subjects: 24
Study 27943153 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg BID plus Bevacizumab 2.5 mg/kg (phase II)
Number of subjects: 24
Study 29798325 — intervention group
Group type: EXPERIMENTAL
Intervention: Yanhouqing buccal tablets (high dose)
Number of subjects: 288
Study 29798325 — intervention group
Group type: EXPERIMENTAL
Intervention: Yanhouqing buccal tablets (low dose)
Number of subjects: 288
Study 29798325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 29798325 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Yanhouqing buccal tablets and placebo)
Number of subjects: 288
Study 24619016 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg (80 mg/day) administered twice daily (4 and 3 hours prior to each radiotherapy fraction)
Number of subjects: 36
Study 24619016 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice daily (4 and 3 hours prior to each radiotherapy fraction)
Number of subjects: 36
Study 24619016 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 36
Study 24619016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 22951179 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 50
Study 22951179 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional epidural anesthesia
Number of subjects: 50
Study 19741581 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day, group A, N. 22)
Number of subjects: 44
Study 19741581 — intervention group
Group type: COMPARATOR
Intervention: Control (group B, N. 22)
Number of subjects: 44
Study 17455838 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (Zymar)
Number of subjects: 35
Study 17455838 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Vigamox)
Number of subjects: 35
Study 17455838 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (Zymar) and Moxifloxacin (Vigamox)
Number of subjects: 35
Study 16418625 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with WAD
Number of subjects: 29
Study 16418625 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 29
Study 14633533 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 50 mg and nicardipine 1 mg, followed by an esmolol infusion 5 microg x kg(‐1) x min(‐1)
Number of subjects: 45
Study 14633533 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 50 mg, followed by an esmolol infusion 5 microg x kg(‐1) x min(‐1)
Number of subjects: 45
Study 14633533 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion as an adjunct to desflurane
Number of subjects: 45
Study 14633533 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 5 mL and 1 mL, followed by a saline infusion at a rate of 0.005 mL x kg(‐1) x min(‐1)
Number of subjects: 45
Study 10540300 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen I: 300 mg dihydroartemisinin + 750 mg mefloquine concurrently
Number of subjects: 207
Study 10540300 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen II: 300 mg dihydroartemisinin + 750 mg mefloquine 24 h later
Number of subjects: 207
Study 10540300 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen III: 300 mg dihydroartemisinin + 750 mg mefloquine at 24 h and 500 mg at 30 h
Number of subjects: 207
Study 10540300 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen IV: 300 mg dihydroartemisinin + 750 mg mefloquine at 0 h and 500 mg at 24 h
Number of subjects: 207
Study 10540300 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 207
Study 10540300 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose mefloquine regimens (III and IV)
Number of subjects: 207
Study 10540300 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who vomited within the first hour of mefloquine administration
Number of subjects: 207
Study 8913125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering of the venous closing pressure within four months of onset of central retinal vein obstruction
Number of subjects: 50
Study 8913125 — intervention group
Group type: COMPARATOR
Intervention: Lowering of the venous closing pressure thereafter
Number of subjects: 50
Study 8913125 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 50